Retro Biosciences

Sam Altman-funded longevity biotech: autophagy pill RTR242 in Phase 1, iPSC-derived blood-stem-cell therapy in its own cGMP plant.

1. Core Product / Service

Retro (founded 2021, Redwood City) pursues three routes to extending healthy lifespan: small molecules, cell therapies and cellular reprogramming [1].

• RTR242 — an oral, first-in-class small molecule designed to restart autophagy. A randomized, placebo-controlled single-ascending-dose Phase 1 in healthy volunteers (ACTRN12625001274460, 50–800 mg) runs at an early-phase unit in Adelaide, Australia; Alzheimer's disease is the intended first patient indication [2][3]. The company says it took ~15 months from indication selection to first dose [4].
• Cell therapy — iPSC-derived hematopoietic stem cells (with Murdoch Children's Research Institute) and an automated-manufacturing partnership with Multiply Labs worth up to $85M [1][5].
• Reprogramming / AI — with openai, a biology-specialized model (GPT-4b micro) designed variants of Yamanaka factors (RetroSOX, RetroKLF) that reportedly raised pluripotency-marker expression >50x; these are self-reported results without independent replication [6].

Wet lab — from shipping containers to cGMP:

2. Target Users & Pain Points

• Its own pipeline, aimed at age-related disease (neurodegeneration, blood/immune aging).
• Pain addressed: aging biology is slow to translate; Retro tries to compress the path to human data (first dosing within ~15 months of choosing an indication) and to own scarce cell-therapy manufacturing capacity.

3. Competitive Landscape

4. Unique Observations

• The only GMP insourcer in its cohort: among US AI-era pipeline startups, Retro is the one that brought GMP manufacturing in-house — driven by cell-therapy CDMO capacity and process know-how, not by small molecules [1].
• Capex frugality as a founding story: the container-lab start is widely retold, but the "Bio-Foundry" label sometimes attached to it is not confirmed, and the ~$200k figure likely excludes equipment [7].
• Altman's vehicle for drug R&D: OpenAI has said it is not building drugs itself; Retro, privately funded by Altman and partnered with OpenAI on models, is one plausible route by which OpenAI-adjacent work reaches the clinic [4][6].

5. Financials / Funding

• Founding capital: $180M from Sam Altman (2021) [7].
• 2026 round: initial close announced 2026-05-22 at a $1.8B pre-money valuation, led by 4P Capital; amount undisclosed [1].
• RTR242 data: the CEO has said no dose-limiting toxicities have been seen; early data had been expected around August / Q3 2026, but no formal data release was found as of 2026-10-14 [3]. An unsourced aggregator claim of a safety failure contradicts the company's statements and is unverified.

6. People & Relationships

• CEO: Joe Betts-LaCroix (founded Vium, later acquired by Recursion); co-leaders include Sheng Ding and Matt Buckley.
• Backers / partners: Sam Altman, 4P Capital, openai, Multiply Labs, Murdoch Children's Research Institute.
• Peers: newlimit, Altos Labs.

Sources

• [1] Retro Biosciences blog, "Fundraise 2026" (2026-05-22; accessed 2026-10-14)
• [2] Longevity.Technology, "Retro Bio commences first-in-human trial" (accessed 2026-10-14)
• [3] Longevity.Technology, "Retro Bio's $1.8b moment" (accessed 2026-10-14); ANZCTR ACTRN12625001274460
• [4] Regen Report / Retro statements on time to first dose (2026-05; accessed 2026-10-14)
• [5] Business Wire, Multiply Labs–Retro $85M partnership (2024-05-14; accessed 2026-10-14)
• [6] OpenAI, "Accelerating life sciences research with Retro Biosciences" (accessed 2026-10-14)
• [7] MIT Technology Review (2023-03-08); Bloomberg Businessweek (2023-12-19) (accessed 2026-10-14)